Celltrion Healthcare presents the first real-world data for Truxima® (biosimilar rituximab) in patients with diffuse large B-cell lymphoma at the EHA 2021 Virtual Congress – Business Wire

CONTEXT:  Presentation at the European Hematology Association (EHA) 2021 Virtual Congress of a post-approval safety study on Truxima (biosimiliar rituximab) in patients with large B-cell lymphoma.  Results showed similar results Continue Reading

Posted On :